Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

NCT00668200 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Paget's Disease of the Bone
Hypocalcemia

Interventions

DRUG: Reclast (ZOL446, zoledronic acid)
DIETARY_SUPPLEMENT: Calcium
DIETARY_SUPPLEMENT: Vitamin D

Sponsor

Novartis Pharmaceuticals